代谢分析

α-玉柏碱减轻大鼠心肌缺血再灌注损伤*

展开
  • 1.南华大学附属南华医院重症医学科,衡阳 421002;
    2.南华大学附属南华医院胸外科,衡阳 421002;
    3.南华大学护理学院基础护理教研室,衡阳 421001;
    4.长沙民政职业技术学院,长沙 410004
第一作者 Tel:18073486068;E-mail:yululiu2009@163.com
**Tel:13975436137;E-mail:yaopingbo752300@126.com

收稿日期: 2021-03-04

  网络出版日期: 2024-06-24

基金资助

*湖南省自然基金青年基金(2018JJ3473)

Reduced myocardial ischemia reperfusion injury in rats with α-obscurine*

Expand
  • 1. The Affiliated Nanhua Hospital, Department of Intensive Care Units, Hengyang Medical School, University of South China, Hengyang 421002, China;
    2. The Affiliated Nanhua Hospital, Department of Thoracic Surgery, Hengyang Medical School, University of South China, Hengyang 421002, China;
    3. Nursing College, Hengyang Medical School, University of South China, Hengyang 421001, China;
    4. Changsha Social Work College, Changsha 410004, China

Received date: 2021-03-04

  Online published: 2024-06-24

摘要

目的: 探索石松的活性成分α-玉柏碱通过抗炎抗氧化作用对心肌缺血再灌注(MI/R)损伤的保护作用。方法: Wistar大鼠灌胃1 mL无菌水或含有2.5 mg·kg-1或5 mg·kg-1 α-玉柏碱的水,持续1周,雷米普利1 mg·kg-1作为阳性对照。结扎心脏左前降支30 min,再灌注3 h。超声检测射血分数EF(%)、短轴缩短分数FS(%)、左心室收缩压LVSP(mmHg)、左心室舒张末期压力LVEDP(mmHg)。伊文思蓝染指示心梗体积。试剂盒检测血清或心肌组织中总还原型谷胱甘肽(GSH)、乳酸脱氢酶(LDH)、天冬氨酸转氨酶(AST)、超氧化物歧化酶(SOD)和丙二醛(MDA)的水平。ELISA测定血清肌酸激酶-同工酶 (CK-Mb)、肌钙蛋白T (cTnT)、肿瘤坏死因子(TNF)-α、白介素(IL)-1β、IL-6和前列腺素E 2(PGE 2)。Western blotting检测环氧合酶2(COX-2)、金属基质蛋白酶(MMP)-2和MMP-9的蛋白表达。结果: 与假手术对照组比,MI/R组大鼠EF、FS和LVSP显著下降,而LVEDP明显升高(P<0.05)。α-玉柏碱能有效逆转这些超声心动指标(P<0.05)。α-玉柏碱还有效减少了MI/R大鼠的梗死面积和血清CK-Mb、cTnT、AST和LDH(P<0.05)。α-玉柏碱降低了MI/R升高的血清MDA、升高了降低的血清SOD和心肌GSH,减轻了氧化应激(P<0.05)。MI/R升高的血清炎症标志物TNF-α、IL-1β、IL-6、PEG2和心肌炎症标志物Cox-2均在5 mg·kg-1·d-1 α-玉柏碱处理下显著降低(P<0.05)。MI/R升高的MMP-2和MMP-9也被α-玉柏碱降低(P<0.05)。结论: α-玉柏碱能有效减轻氧化应激和炎症,改善MI/R导致的心肌损伤。对MMP-2和MMP-9的抑制可能是其作用机制。

本文引用格式

刘雨露, 朱子贵, 张建新, 赵红, 姚平波 . α-玉柏碱减轻大鼠心肌缺血再灌注损伤*[J]. 药物分析杂志, 2022 , 42(2) : 287 -293 . DOI: 10.16155/j.0254-1793.2022.02.13

Abstract

Objective: To explore the protective effect of α-obscurine, an active component of Lycopodium on myocardial ischemia-reperfusion (MI/R) injury via anti-inflammatory and anti-oxidant ways. Methods: Wistar rats were intragastrically administered with 1 mL of sterile water or water containing 2.5 mg·kg-1 or 5 mg·kg-1 α-obscurine for 1 week. Ramipril 1 mg·kg-1 was used as a positive control. The left anterior descending branch of the heart was ligated for 30 min and reperfused for 3 h. Echocardiograph was employed to test the the ejection fraction (EF, %), short axis shortening fraction (FS, %), left ventricular systolic pressure (LVSP, mmHg) and left ventricular end diastolic pressure (LVEDP, mmHg). The volume of myocardial infarction was indicated with Evans blue staining. The kits detect total reduced glutathione (GSH), lactate dehydrogenase (LDH), aspartate aminotransferase (AST), superoxide dismutase (SOD) and malondialdehyde (MDA) in serum or myocardial tissue. ELISA was used to test serum creatine kinase-isoenzyme (CK-Mb), troponin T (cTnT), tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6 and prostaglandin E2 (PGE2). Western blotting detects the protein expression of cyclooxygenase 2 (COX-2), metal matrix protease (MMP)-2 and MMP-9. Results: Compared with sham operation control group, EF, FS, and LVSP in MI/R group were significantly decreased, while the LVEDP was significantly increased (P<0.05). α-obscurine could effectively reverse these echocardiographic indexes (P<0.05). α-obscurine also effectively reduced the infarct size of MI/R rats and the serum indicators of myocardial injury such as CK-Mb, cTnT, AST and LDH (P<0.05). α-obscurine reduced the serum MDA with elevated MI/R, increased the reduced serum SOD and myocardial GSH, and alleviated the oxidative stress in MI/R rats (P<0.05). Elevated serum inflammation markers TNF-α, IL-1β, IL-6, PEG2 and myocardial inflammation marker Cox-2 were significantly reduced under 5 mg·kg-1·d-1 α-obscurine treatment (P<0.05). It was further found that metalloproteinase (MMP)-2 and MMP-9 with elevated MI/R were also reduced by α-obscurine (P<0.05). Conclusion: Our results show that α-obscurine could effectively reduce oxidative stress and inflammation, and improve myocardial damage caused by MI/R. The inhibition of MMP-2 and MMP-9 may be its mechanism of action.

参考文献

[1] VIRANI SS, ALONSO A, BENJAMIN EJ, et al. Heart disease and stroke statistics-2020 update: a report from the american heart association[J].Circulation, 2020, 141(9):e139
[2] GUNATA M, PARLAKPINAR H. A review of myocardial ischaemia/reperfusion injury: pathophysiology, experimental models, biomarkers, genetics and pharmacological treatment[J].Cell Biochem Funct, 2021, 39(2):190
[3] NAITO H, NOJIMA T, FUJISAKI N, et al. Therapeutic strategies for ischemia reperfusion injury in emergency medicine[J].Acute Med Surg, 2020, 7(1):e501
[4] 刘静, 年华, 徐熠, 等. 伸筋草生物碱对佐剂性关节炎大鼠的抗炎作用及机制研究[J].药物评价研究, 2019, 42(5):869
LIU J, NIAN H, XU Y, et al. Anti-inflammatory effect and mechanism of Shenjincao alkaloids on adjuvant arthritis rats [J].Drug Eval Res, 2019, 42(5):869
[5] JO A, EEN KIM C, LEE M. Serratane triterpenoids isolated from Lycopodium clavatum by bioactivity-guided fractionation attenuate the production of inflammatory mediators[J].Bioorg Chem, 2020, 96(96):103632
[6] 王毅红, 张春生, 谭萍, 等. 石松黄酮类化合物的抗氧化作用研究[J].湖南文理学院学报(自然科学版), 2013, 25(2):30
WANG YH, ZHANG CS, TAN P, et al.On anti-oxidation of the Lycopodium japonicum thunb flavonoids [J].J Hunan Univ Arts(Nat Sci Ed), 2013, 25(2):30
[7] 邹桂欣, 尤献民, 吴怡. DPPH·法评价伸筋草不同提取物清除自由基的能力[J].药物评价研究, 2012, 35(5):359
ZOU GX, YOU XM, WU Y. Evaluation of free radical scavenging ability of different extracts from Lycopodii Herba by DPPH·assay [J].Drug Eval Res, 2012, 35(5):359
[8] 邹桂欣, 尤献民, 邸子真. 伸筋草提取物中玉柏碱在大鼠体内的药动学研究[J].药物评价研究, 2013, 36(6):410
ZOU GX, YOU XM, DI ZZ. In vivo pharmacokinetic study on α-obscurine in rats after ig administration of Lycopodium japonicum extract [J].Drug Eval Res, 2013, 36(6):410
[9] 张妍妍, 毕悦, 尹丽颖, 等. 伸筋草总生物碱的提取纯化与急性毒性及抗炎活性研究[J].中医药学报, 2020, 48(6):14
ZHANG YY, BI Y, YIN LY, et al. Extraction and purification of total alkaloids from Lycopodii Herba and the study on its acute toxicity and anti-inflammatory activity [J].J Chin Med Pharmacol, 2020, 48(6):14
[10] BANERJEE A, PATHAK S, JOTHIMANI G, et al. Antiproliferative effects of combinational therapy of Lycopodium clavatum and quercetin in colon cancer cells[J].J Basic Clin Physiol Pharmacol, 2020, 31(4):20190193
[11] DELEON-PENNELL KY, ALTARA R, YABLUCHANSKIY A, et al. The circular relationship between matrix metalloproteinase-9 and inflammation following myocardial infarction[J].IUBMB Life, 2015, 67(8):611
[12] LI X, KANG M, MA N, et al. Identification and analysis of chemical constituents and rat serum metabolites in Lycopodium clavatum using UPLC-Q-TOF/MS combined with multiple data-processing approaches[J].Evid Based Comp Alternat Med, 2019, 2019:5165029
[13] JIANG F, QI B, DING N, et al. Lycopodium alkaloids from Huperzia Serrata[J].Fitoterapia, 2019, 137(137):104277
[14] KIM THU D, VUI DT, NGOC HN, et al. The use of Huperzia species for the treatment of Alzheimer's disease[J].J Basic Clin Physiol Pharmacol, 2019, 31(3):20190159
[15] JAYARAJ RL, BEIRAM R, AZIMULLAH S, et al. Lycopodium attenuates loss of dopaminergic neurons by suppressing oxidative stress and neuroinflammation in a rat model of parkinson's disease[J].Molecules, 2019, 24(11):2182
[16] 邹桂欣, 尤献民, 刘晶, 等. 伸筋草提取物及主要药效成分对家兔血小板聚集影响[J].亚太传统医药, 2012, 8(11):10
ZOU GX, YOU XM, LIU J, et al. Effects of extracts and active constituent from Lycopodium on platelet aggregation in rabbit [J].Asia-Pacific Tradit Med, 2012, 8(11):10
[17] FLUCK F, AUGUSTIN AM, BLEY T, et al. Current treatment options in acute limb ischemia[J].Rofo, 2020, 192(4):319
[18] POWERS WJ. Acute ischemic stroke[J].N Engl J Med, 2020, 383(3):252
[19] WU Y, LIU H, WANG X. Cardioprotection of pharmacological postconditioning on myocardial ischemia/reperfusion injury[J].Life Sci, 2021, 264(264):118628
[20] SCOFIELD SLC, DALAL S, LIM KA, et al. Exogenous ubiquitin reduces inflammatory response and preserves myocardial function 3 days post-ischemia-reperfusion injury[J].Am J Physiol Heart Circ Physiol, 2019, 316(3):H617
[21] CHAN BYH, ROCZKOWSKY A, CHO WJ, et al. Junctophilin-2 is a target of matrix metalloproteinase-2 in myocardial ischemia-reperfusion injury[J].Basic Res Cardiol, 2019, 114(6):42
[22] GÖMÖRI K, SZABADOS T, KENYERES É, et al. Cardioprotective effect of novel matrix metalloproteinase inhibitors[J].Int J Mol Sci, 2020, 21(19): 6990
文章导航

/